COVID-19 and HIV

Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medicine, New York, NY



CME VIDEOTop of page

About the Presenter:Top of page

Roy Gulick’s research interests include designing, conducting, and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He is PI of the Cornell-New Jersey HIV Clinical Trials Unit of the ACTG and the HPTN, sponsored by the NIH. He also serves as the Co-Chair of the DHHS Panel on Clinical Practices for Treatment of HIV Infection, Chair of the NIH Office of AIDS Research Advisory Committee, and previously served as Chairman of the Antiviral Drugs Advisory Committee of the FDA.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • To discuss the clinical features of COVID-19 in the setting of HIV infection
  • To identify current and prospective COVID-19 treatments for people living with HIV
  • To review current guidelines for people living with HIV in the time of COVID-19

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for September 9, 2020 as a live activity.  This activity will also be available as an enduring activity from September 10, 2020, through September 9,2023.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity. - Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose. - Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. - Dr. Roy M. Gulick (Presenter) has no relevant financial relationships to disclose. Dr. Gulick will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register